This month on Synapse
Our Taylor Wessing and Willke Farr & Gallagher experts discuss the pricing and reimbursement process for biosimilars in the US, the UK, France, Germany and the Netherlands, and the line between competition and a breach of antitrust rules as it applies to this market.
Paul England and Matthew Royle explain the reasoning of the UK Supreme Court Warner-Lambert decision and its implications for how infringement of second medical use claims will be assessed in the UK.
Judith Krens and Marthe Riewald reports a decision from the Netherlands in which a new therapeutic application of a known active substance could qualify for an SPC.
Paul England examines recent developments allowing prescription of medicinal cannabis for certain conditions.
Paul England looks at recent speculation about the Unified Patent Court and Unitary Patent.
